Home
SUPN
SUPN News

Latest Supernus Pharmaceuticals Inc. (SUPN) News on March 27, 2025

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.

Investor's Business Daily

2 days ago

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.

Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks

StockStory

6 days ago

Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks

Down -20.07% in 4 Weeks, Here's Why Supernus (SUPN) Looks Ripe for a Turnaround

Zacks

10 days ago

Down -20.07% in 4 Weeks, Here's Why Supernus (SUPN) Looks Ripe for a Turnaround

Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks

StockStory

13 days ago

Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks

3 Small-Cap Stocks Skating on Thin Ice

StockStory

14 days ago

3 Small-Cap Stocks Skating on Thin Ice

Supernus Pharmaceuticals, Inc. (SUPN): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts

Insider Monkey

20 days ago

Supernus Pharmaceuticals, Inc. (SUPN): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts

Argus Research

22 days ago

SUPN: Lowering target price to $33.00

Supernus to Participate in Two Upcoming Investor Conferences

GlobeNewswire

23 days ago

Supernus to Participate in Two Upcoming Investor Conferences

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

StockStory

23 days ago

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers

StockStory

23 days ago

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers

Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals?

Simply Wall St.

24 days ago

Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals?

Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stock to Buy Now?

Insider Monkey

25 days ago

Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stock to Buy Now?

Supernus to Participate in the TD Cowen 45th Annual Health Care Conference

GlobeNewswire

a month ago

Supernus to Participate in the TD Cowen 45th Annual Health Care Conference

Thomson Reuters StreetEvents

a month ago

Q4 2024 Supernus Pharmaceuticals Inc Earnings Call

MT Newswires

a month ago

Supernus Pharmaceuticals Q4 Earnings, Revenue Rise; Provides 2025 Revenue Guidance

Supernus Pharmaceuticals Inc (SUPN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...

GuruFocus.com

a month ago

Supernus Pharmaceuticals Inc (SUPN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...

Argus Research

a month ago

SUPN: Lowering target price to $34.00

Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks

a month ago

Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates

Zacks

a month ago

Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates

Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers

StockStory

a month ago

Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers

Associated Press Finance

a month ago

Supernus: Q4 Earnings Snapshot

Supernus Announces Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

a month ago

Supernus Announces Fourth Quarter and Full Year 2024 Financial Results

What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings

StockStory

a month ago

What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 Earnings

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

Benzinga

a month ago

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

MT Newswires

a month ago

Cantor Fitzgerald Downgrades Supernus Pharmaceuticals to Neutral From Overweight, Cuts Price Target to $36 From $57

MT Newswires

a month ago

Supernus Pharma Sinks Premarket After Treatment-Resistant Depression Study Misses Primary Endpoint

Argus Research

a month ago

SUPN: Raising target price to $42.00

Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression

GlobeNewswire

a month ago

Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression

Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

a month ago

Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade

Zacks

2 months ago

Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade

Supernus wins FDA approval for Parkinson’s pump on fourth try

Pharmaceutical Technology

2 months ago

Supernus wins FDA approval for Parkinson’s pump on fourth try

Argus Research

2 months ago

SUPN: Raising target price to $42.00

MT Newswires

2 months ago

Supernus Pharmaceuticals Says Onapgo Approved by FDA for Parkinson's Disease

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease

GlobeNewswire

2 months ago

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease

7MM PD market to grow by $4.5bn between 2023 and 2033

Clinical Trials Arena

2 months ago

7MM PD market to grow by $4.5bn between 2023 and 2033

Argus Research

2 months ago

SUPN: What does Argus have to say about SUPN?

MT Newswires

2 months ago

Supernus Pharmaceuticals Says US FDA Approves Label Update for ADHD Treatment Qelbree

Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women

GlobeNewswire

2 months ago

Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women

Argus Research

2 months ago

SUPN: Raising target price to $41.00

Argus Research

2 months ago

SUPN: Raising target price to $40.00

Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 9.4% CAGR over the last five years

Simply Wall St.

3 months ago

Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 9.4% CAGR over the last five years

MT Newswires

3 months ago

Cantor Fitzgerald Initiates Supernus Pharmaceuticals at Overweight With $57 Price Target

Argus Research

3 months ago

SUPN: Lowering target price to $39.00

Argus Research

3 months ago

SUPN: Rating increased to a BUY

Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada

GlobeNewswire

3 months ago

Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada

Argus Research

4 months ago

SUPN: What does Argus have to say about SUPN?

Argus Research

4 months ago

SUPN: Raising target price to $39.00

Argus Research

4 months ago

SUPN: Raising target price to $38.00

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

GlobeNewswire

4 months ago

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference

GlobeNewswire

4 months ago

Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference

Argus Research

4 months ago

SUPN: Raising target price to $40.00

MT Newswires

4 months ago

Supernus Pharmaceuticals Insider Sold Shares Worth $4,536,250, According to a Recent SEC Filing

MT Newswires

4 months ago

Supernus Pharmaceuticals Insider Sold Shares Worth $391,568, According to a Recent SEC Filing

MT Newswires

5 months ago

Supernus Pharmaceuticals Insider Sold Shares Worth $520,480, According to a Recent SEC Filing

Supernus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

5 months ago

Supernus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Argus Research

5 months ago

SUPN: What does Argus have to say about SUPN?

Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

5 months ago

Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

MT Newswires

5 months ago

Supernus Pharmaceuticals Q3 Swings to Profit, Revenue Increases; 2024 Revenue Outlook Lifted

Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks

5 months ago

Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates

Zacks

5 months ago

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates

Associated Press Finance

5 months ago

Supernus: Q3 Earnings Snapshot

Supernus Announces Third Quarter 2024 Financial Results

GlobeNewswire

5 months ago

Supernus Announces Third Quarter 2024 Financial Results

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

GlobeNewswire

5 months ago

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

GlobeNewswire

5 months ago

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

Supernus’ depression drug improved symptoms in two hours in Phase IIa study

Clinical Trials Arena

5 months ago

Supernus’ depression drug improved symptoms in two hours in Phase IIa study

MT Newswires

5 months ago

Supernus Pharmaceuticals Reports 'Promising' Data in Trial of Anti-Depression Drug Candidate

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

GlobeNewswire

5 months ago

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

GlobeNewswire

6 months ago

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

6 months ago

Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Argus Research

6 months ago

SUPN: What does Argus have to say about SUPN?

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree

GlobeNewswire

6 months ago

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree

Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?

Simply Wall St.

6 months ago

Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

GlobeNewswire

6 months ago

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Supernus Pharmaceuticals (SUPN) Slid on Disappointing Progress Report on a Key Drug

Insider Monkey

6 months ago

Supernus Pharmaceuticals (SUPN) Slid on Disappointing Progress Report on a Key Drug

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug

Benzinga

7 months ago

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

GlobeNewswire

7 months ago

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

Argus Research

7 months ago

SUPN: What does Argus have to say about SUPN?

Argus Research

7 months ago

SUPN: Raising target price to $28.00

MT Newswires

7 months ago

Supernus Pharmaceuticals Says US FDA Accepts NDA Resubmission for Potential Parkinson's Related Treatment Device

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

GlobeNewswire

7 months ago

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

Some May Be Optimistic About Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings

Simply Wall St.

7 months ago

Some May Be Optimistic About Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings

Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?

Zacks

8 months ago

Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?

Supernus Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

8 months ago

Supernus Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations

Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks

8 months ago

Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say

Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates

Zacks

8 months ago

Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates

Associated Press Finance

8 months ago

Supernus: Q2 Earnings Snapshot

Supernus Announces Second Quarter 2024 Financial Results

GlobeNewswire

8 months ago

Supernus Announces Second Quarter 2024 Financial Results

MT Newswires

8 months ago

Supernus Pharmaceuticals Resubmits Marketing Application for Parkinson's Treatment Device

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

GlobeNewswire

8 months ago

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

Those who invested in Supernus Pharmaceuticals (NASDAQ:SUPN) three years ago are up 13%

Simply Wall St.

8 months ago

Those who invested in Supernus Pharmaceuticals (NASDAQ:SUPN) three years ago are up 13%

Argus Research

8 months ago

SUPN: Raising target price to $24.00

Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024

GlobeNewswire

8 months ago

Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024

Argus Research

8 months ago

SUPN: Raising target price to $23.00

Argus Research

9 months ago

SUPN: What does Argus have to say about SUPN?

VanEck Semiconductor ETF Is Riskier Than You Think

Motley Fool

10 months ago

VanEck Semiconductor ETF Is Riskier Than You Think

A Wall Street Analyst Just Predicted Nvidia Would Hit a $10 Trillion Market Cap. Is That Actually Possible?

Motley Fool

10 months ago

A Wall Street Analyst Just Predicted Nvidia Would Hit a $10 Trillion Market Cap. Is That Actually Possible?

Norway wealth fund to vote against Musk's $56 billion Tesla pay package

Reuters

10 months ago

Norway wealth fund to vote against Musk's $56 billion Tesla pay package

Oberstdorfer Bergbahn Reports Full Year 2023 Earnings

Simply Wall St.

10 months ago

Oberstdorfer Bergbahn Reports Full Year 2023 Earnings

Director Gregory Pipkin Sells 82,238 Shares of Sable Offshore Corp (SOC)

GuruFocus.com

10 months ago

Director Gregory Pipkin Sells 82,238 Shares of Sable Offshore Corp (SOC)

Insider Sale: CFO Steven Tomsic Sells 30,000 Shares of Fox Corp (FOX)

GuruFocus.com

10 months ago

Insider Sale: CFO Steven Tomsic Sells 30,000 Shares of Fox Corp (FOX)

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use